RVNC

Revance Therapeutics, Inc. [RVNC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RVNC Stock Summary

Top 10 Correlated ETFs

RVNC


Top 10 Correlated Stocks

RVNC


In the News

08:01 28 Mar 2024 RVNC

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.

10:50 28 Mar 2024 RVNC

Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Seamus Fernandez - Guggenheim Partners Mikaela Franceschina - Barclays David Amsellem - Piper Sandler Stacy KU - TD Cowen Annabel Samimy - Stifel Uy Ear - Mizuho Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Terence Flynn - Morgan Stanley Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.

08:17 28 Mar 2024 RVNC

Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

05:51 28 Mar 2024 RVNC

Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn

Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.

02:27 28 Mar 2024 RVNC

3 Healthcare Stocks to Sell in September Before They Crash & Burn

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.

12:43 28 Mar 2024 RVNC

3 Very Oversold Biotech Stocks to Buy Right Now

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.

08:53 28 Mar 2024 RVNC

Revance shares gain 8% after FDA approval of cervical dystonia treatment

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.

08:06 28 Mar 2024 RVNC

Revance's Botox rival gets FDA approval for painful neck muscle condition

The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.

07:41 28 Mar 2024 RVNC

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.

11:08 28 Mar 2024 RVNC

After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

RVNC Financial details

Company Rating
Neutral
Market Cap
507.52M
Income
-330.24M
Revenue
234.04M
Book val./share
-1.68
Cash/share
2.82
Dividend
-
Dividend %
-
Employees
597
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-1.45
Forward P/E
-4.66
PEG
0.68
P/S
2.88
P/B
-5.73
P/C
1.75
P/FCF
-2.68
Quick Ratio
3.96
Current Ratio
4.73
Debt / Equity
-2.89
LT Debt / Equity
-2.81
-
-
EPS (TTM)
-3.86
EPS next Y
-1.06
EPS next Q
-0.48
EPS this Y
-21.84%
EPS next Y
-72.63%
EPS next 5Y
-146.37%
EPS last 5Y
1.25%
Revenue last 5Y
255.36%
Revenue Q/Q
22.94%
EPS Q/Q
-61.96%
-
-
-
-
SMA20
-13.13%
SMA50
-28.01%
SMA100
-38.92%
Inst Own
72.51%
Inst Trans
0.72%
ROA
-79%
ROE
1793%
ROC
-0.75%
Gross Margin
62%
Oper. Margin
-158%
Profit Margin
-196%
Payout
-
Shs Outstand
104.21M
Shs Float
93.53M
-
-
-
-
Target Price
32
52W Range
4.77-37.98
52W High
-86.65%
52W Low
+23.5%
RSI
41.26
Rel Volume
0.87
Avg Volume
1.81M
Volume
1.57M
Perf Week
0%
Perf Month
-5.36%
Perf Quarter
-53.18%
Perf Half Y
-60.64%
-
-
-
-
Beta
1.09
-
-
Volatility
0.18%, 0.62%
Prev Close
5.11%
Price
4.94
Change
5.11%

RVNC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.261.151.822.77
Net income per share
-3.6-4.86-4.25-4.9-3.83
Operating cash flow per share
-2.44-3.08-3.28-2.66-2.56
Free cash flow per share
-2.52-3.15-3.55-2.98-2.64
Cash per share
6.687.523.344.693.01
Book value per share
5.196.451.010.17-1.79
Tangible book value per share
5.192.69-1.98-1.26-1.91
Share holders equity per share
5.196.451.010.17-1.79
Interest debt per share
0.683.924.95.985.4
Market cap
705.05M1.64B1.1B1.34B743.63M
Enterprise value
563.23M1.52B1.31B1.65B1.08B
P/E ratio
-4.51-5.83-3.84-3.77-2.3
Price to sales ratio
1.71K107.2714.1510.133.18
POCF ratio
-6.64-9.21-4.97-6.94-3.43
PFCF ratio
-6.44-9-4.59-6.2-3.33
P/B Ratio
3.134.3916.08106.53-4.91
PTB ratio
3.134.3916.08106.53-4.91
EV to sales
1.36K99.3516.912.464.63
Enterprise value over EBITDA
-3.54-5.78-5.04-6.84-5.24
EV to operating cash flow
-5.31-8.53-5.94-8.53-5.01
EV to free cash flow
-5.15-8.33-5.49-7.63-4.85
Earnings yield
-0.22-0.17-0.26-0.27-0.44
Free cash flow yield
-0.16-0.11-0.22-0.16-0.3
Debt to equity
0.130.574.7433.21-2.89
Debt to assets
0.090.290.610.720.91
Net debt to EBITDA
0.890.46-0.82-1.28-1.64
Current ratio
7.247.383.664.953.8
Interest coverage
0-18.03-43.79-16.52-11.4
Income quality
0.670.630.790.540.67
Dividend Yield
00.16000
Payout ratio
0-0.960-0.020
Sales general and administrative to revenue
150.159.770.360.030.17
Research and developement to revenue
249.068.211.490.760.32
Intangibles to total assets
00.30.380.180.02
Capex to operating cash flow
0.030.020.080.120.03
Capex to revenue
-7.84-0.28-0.23-0.17-0.03
Capex to depreciation
-1.11-0.41-0.91-0.59-0.5
Stock based compensation to revenue
43.392.380.560.390.2
Graham number
20.4926.579.854.3712.43
ROIC
-0.57-0.44-0.64-0.58-0.68
Return on tangible assets
-0.46-0.56-0.87-0.75-0.69
Graham Net
4.041.64-3.41-2.9-3.92
Working capital
255.62M389.04M178.83M299.05M249.64M
Tangible asset value
225.49M155.98M-133.83M-91.58M-161.41M
Net current asset value
181.81M104.07M-216.58M-194.57M-291.19M
Invested capital
0.130.574.7433.21-2.89
Average receivables
13.5M914.5K2.59M7.34M19.51M
Average payables
8.22M10.33M11.63M7.57M9.18M
Average inventory
02.94M8.02M14.24M31.95M
Days sales outstanding
043.5615.7131.2243.16
Days payables outstanding
28.42968.72165.3232.1257.24
Days of inventory on hand
0449.73158.32129.46188.93
Receivables turnover
08.3823.2411.698.46
Payables turnover
12.840.382.2111.376.38
Inventory turnover
00.812.312.821.93
ROE
-0.69-0.75-4.19-28.292.14
Capex per share
-0.07-0.07-0.27-0.32-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.620.610.690.660.77
Net income per share
-1.8-0.81-0.8-1.63-0.62
Operating cash flow per share
-0.38-0.86-0.64-0.59-0.47
Free cash flow per share
-0.64-0.87-0.63-0.64-0.49
Cash per share
4.253.383.823.472.82
Book value per share
0.16-0.330.32-1.23-1.68
Tangible book value per share
-1.14-1.66-0.94-1.35-1.79
Share holders equity per share
0.16-0.330.32-1.23-1.68
Interest debt per share
5.275.435.225.694.91
Market cap
1.48B2.61B2.12B993.43M792.38M
Enterprise value
1.79B2.91B2.41B1.3B1.13B
P/E ratio
-2.56-9.89-7.87-1.76-3.56
Price to sales ratio
29.6352.9836.4317.511.35
POCF ratio
-49.01-37.6-39.68-19.49-18.54
PFCF ratio
-28.85-37.14-39.88-17.91-17.8
P/B Ratio
117.39-97.9879.07-9.35-5.23
PTB ratio
117.39-97.9879.07-9.35-5.23
EV to sales
35.8359.0441.4422.9316.23
Enterprise value over EBITDA
-31.85-54.65-39.62-32.76-21.92
EV to operating cash flow
-59.26-41.9-45.13-25.55-26.51
EV to free cash flow
-34.89-41.39-45.36-23.47-25.45
Earnings yield
-0.1-0.03-0.03-0.14-0.07
Free cash flow yield
-0.03-0.03-0.03-0.06-0.06
Debt to equity
33.21-16.3416.14-4.59-2.89
Debt to assets
0.720.80.720.920.91
Net debt to EBITDA
-5.51-5.61-4.79-7.76-6.59
Current ratio
4.954.145.124.733.8
Interest coverage
-19.89-12.9-15-27.35-9.84
Income quality
0.211.160.790.360.77
Dividend Yield
00000
Payout ratio
-0.01-0.06-0.01-0.030
Sales general and administrative to revenue
1.821.291.311.19-2.42
Research and developement to revenue
0.390.470.390.230.28
Intangibles to total assets
0.180.20.180.020.02
Capex to operating cash flow
0.70.0100.090.04
Capex to revenue
-0.42-0.020-0.08-0.03
Capex to depreciation
-1.15-0.130.08-2.12-1.25
Stock based compensation to revenue
0.210.270.270.180.13
Graham number
2.532.452.416.714.84
ROIC
-0.16-0.14-0.13-0.32-0.16
Return on tangible assets
-0.3-0.15-0.14-0.27-0.12
Graham Net
-2.63-3.39-2.64-3.42-3.68
Working capital
299.05M245.04M304.87M306.36M249.64M
Tangible asset value
-91.58M-135.07M-78.85M-116.71M-161.41M
Net current asset value
-194.57M-251.45M-191.8M-250.17M-291.19M
Invested capital
33.21-16.3416.14-4.59-2.89
Average receivables
11.54M13.36M16.21M21.23M26.55M
Average payables
2.65M8.77M10.67M6.56M9.29M
Average inventory
17.75M23.05M31.11M40.33M45.9M
Days sales outstanding
20.4428.0526.3940.2935.69
Days payables outstanding
17.472.3335.2522.1465.79
Days of inventory on hand
70.14154.58145.51214.25217.15
Receivables turnover
4.43.213.412.232.52
Payables turnover
5.171.242.554.071.37
Inventory turnover
1.280.580.620.420.41
ROE
-11.472.48-2.511.330.37
Capex per share
-0.26-0.010-0.05-0.02

RVNC Frequently Asked Questions

What is Revance Therapeutics, Inc. stock symbol ?

Revance Therapeutics, Inc. is a US stock , located in Nashville of Tn and trading under the symbol RVNC

Is Revance Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $33.5. The lowest prediction is $24 and the highest is $38

What is RVNC stock prediction ?

What is Revance Therapeutics, Inc. stock quote today ?

Revance Therapeutics, Inc. stock price is $4.94 today.

Is Revance Therapeutics, Inc. stock public?

Yes, Revance Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap